Cooperative Agreement R43CA221535

The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...

This Project Grant award of $449,996 from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports a collaborative effort between researchers at the University of Minnesota and the University of Cambridge to develop a highly sensitive, low-cost sensor platform for detecting circulating tumor DNA (ctDNA), a key biomarker for early cancer diagnosis. The project aims to combine microwave photonics (MWP) and polymer-based micro-ring resonator technology to create a portable...

This $692,491 Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to develop a minimally-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The primary goal is to investigate early epigenetic signatures for common cancers, including prostate, lung, colorectal, and ovarian cancer, using the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer...

The National Cancer Institute (NCI) awarded a $452,540 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the use of electronic nose (e-nose) technology to predict and assess response to induction therapy, as well as identify recurrence, in patients with locally advanced non-small cell lung cancer. The research aims to develop a non-invasive approach using volatile organic...

This $431,220 National Science Foundation project grant supports the development of a novel part-brain, part-engineered gas sensor for noninvasive detection of lung cancer at Michigan State University from February 1, 2023 to January 31, 2028. The grant is funded through the NSF Directorate for Engineering's Engineering program (CFDA 47.041), which seeks to foster innovation and excellence in engineering research. Specifically, the university will develop a gas sensing device that utilizes...

This Project Grant award for $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel, non-invasive urine test for early detection of kidney cancer. The primary objectives are to: Demonstrate the specificity and accuracy of a biomarker for detecting early-stage renal tumors in kidney cancer patients without symptoms. Demonstrate the effectiveness and accuracy of the test for detecting residual...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $2,078,214 Project Grant to Precision Epigenomics Inc., a University of Arizona Cancer Center and Department of Pathology spin-out, to develop and validate the Sentinel-MPE liquid biopsy assay - a multi-cancer detection test that can identify over twenty different cancer types. The project aims to establish the diagnostic value of the Sentinel-MPE test and validate its use for cancer detection in...

This Project Grant award of $592,866, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports the development of ingestible nanosensors for breath-based detection of early-stage colorectal cancer (CRC). The project aims to engineer nanosensors that can sense specific enzymes in the intestinal mucosa related to tumor development and release volatile reporter signals that can be detected in a person's breath via mass spectrometry. This non-invasive...

This $415,830 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring in ovarian cancer patients. The key products and services to be delivered include: Incorporation of single extracellular vesicle (EV) capture and analysis using plasmonic nanodisk arrays, CRISPR/Cas13a sensors for lysis-free,...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...